NCT05565729View on ClinicalTrials.gov

A Phase I Study of LY3471851 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

October 5, 2022

Primary Completion Date

February 23, 2023

Study Completion Date

February 23, 2023

Conditions
Healthy
Interventions
DRUG

LY3471851

Administered SC.

DRUG

Placebo

Administered SC.

DRUG

Levocetirizine

Administered orally.

Trial Locations (1)

75247

Covance Dallas, Dallas

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Nektar Therapeutics

INDUSTRY